Last week, the Physicians Coalition for Injectable Safety announced its support of recent actions by the Kansas State Board of Healing Arts greatly restricting the use of Lipodissolve, a controversial fat-dissolving injection. According to the Coalition, the board's decision is "appropriate and significant in protecting consumer safety and restricting treatment of non-FDA-approved, compounded, injectable substances into the human body."

The Coalition, formed by the American Society for Aesthetic Plastic Surgery, The American Academy of Facial Plastic and Reconstructive Surgeons, and the American Society of Ophthalmic Plastic and Reconstructive Surgery, is a partnership aimed at protecting consumer safety as it relates to injectable fillers.

On August 18, the Kansas Board announced that patients may not receive Lipodissolve unless authorized by a physician as part of an investigational drug trial. The restriction should take effect September 15. To date, no formal studies of Lipodissolve have demonstrated efficacy or safety. Complications may include skin infection, disfigurement, severe cramping, bloating, and dehydration.